Kotasek 2002.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 161, lung, breast, gastrointestinal, genitourinary, gynecological, other cancer (stage I‐IV); concomitant treatment: chemotherapy
Interventions	drug = Darbepoetin alpha dose = a: 9 µg/kg sc Q4W, b: 12 µg/kg sc Q4W, c: 15 µg/kg sc Q4W, d: 18 µg/kg sc Q4W hb‐target = 13‐14 g/dL (women), 13‐15 g/dL (men) planned ESA duration = 12 weeks
Outcomes	Primary: safety; secondary: determine effective dose, effect of ESA, QoL feasibility
Notes	study number = 26117
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Low risk	central randomization